OncoSec to Present at the Raymond James Human Health Innovation Conference

Rhea-AI Summary

OncoSec Medical Incorporated (NASDAQ:ONCS) will present an overview at the Raymond James Human Health Innovation Conference from June 21 to June 23, 2021. The presentation is scheduled for 12:00pm ET on June 21. For those unable to attend, a replay will be available on OncoSec's website for 90 days. OncoSec focuses on developing cytokine-based immunotherapies, particularly TAVO™, aimed at enhancing the immune response against cancer. The company continues to explore new therapeutic candidates for various cancer types.

PENNINGTON, N.J. and SAN DIEGO, May 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced that management will present a company overview at the Raymond James Human Health Innovation Conference being held virtually Monday, June 21^st – Wednesday, June 23^rd, 2021.

Raymond James Human Health Innovation Virtual Conference
Date: Monday, June 21^st  
Time: 12:00pm ET

For those not attending the conference, a replay of the presentation will be available for 90 days in the "Events & Presentations" section of OncoSec's website at https://ir.oncosec.com/events-presentations.  

About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the "Company," "OncoSec," "we" or "our") is a biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy investigational product candidate – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach along with an acceptable safety profile, warranting further development. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions. For more information, please visit www.oncosec.com.

TAVO™ is a trademark of OncoSec Medical Incorporated.

Company Contact
Brian Leuthner
Chief Operating Officer
investors@oncosec.com

Media Contact
Patrick Bursey
LifeSci Communications
+1-646-970-4688
pbursey@lifescicomms.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-at-the-raymond-james-human-health-innovation-conference-301300655.html

SOURCE OncoSec Medical Incorporated

FAQ

When will OncoSec present at the Raymond James conference?

OncoSec will present on June 21, 2021, at 12:00pm ET.

Where can I find the OncoSec conference presentation replay?

The replay will be available for 90 days in the 'Events & Presentations' section of OncoSec's website.

What is TAVO™ by OncoSec?

TAVO™ is OncoSec's lead investigational immunotherapy using IL-12 to stimulate the immune system against cancer.

What is the focus of OncoSec's research?

OncoSec is focused on developing cytokine-based immunotherapies to target and attack various cancers.

What are OncoSec's planned developments beyond TAVO™?

OncoSec is developing new DNA-encoded therapeutic candidates and targeting deep visceral lesions.